ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag big pharma microbiology immunology

A needle drawing up fluid from an unlabeled vial.
Cancer Vaccination as a Promising New Treatment Against Tumors
Shelby Bradford, PhD | Mar 15, 2024 | 10+ min read
Vaccination has beaten back infections for more than a century. Now, it may be the next big step in battling cancer.
Bugs as Drugs to Boost Cancer Therapy
Danielle Gerhard, PhD | Jan 18, 2024 | 7 min read
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
monoclonal antibody antibodies sars-cov-2 covid-19 coronavirus pandemic eli lilly receptor binding domain spike protein
First Antibody Trial Launched in COVID-19 Patients
Katarina Zimmer | Jun 2, 2020 | 8 min read
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.
Bioterrorism Research: New Money, New Anxieties
John Dudley Miller | Apr 6, 2003 | 8 min read
Ned Shaw US scientists have reason to feel both heady and scared. The federal government recently released unprecedented billions of dollars to fund bioterrorism research. Yet, the merits of this sudden shift in focus are being debated, and some worry that the money will be squandered or wasted. "I have been really very upset by the focus on bioterrorism," says Stanley Falkow, professor of microbiology and immunology and of medicine at Stanford University. "Everybody's talking about it, but th
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
One Step Beyond: Going Beyond Genomics With Proteomics And Two-Dimensional Gel Technology
Laura Defrancesco | Jan 3, 1999 | 10+ min read
Proteomes and 2D Gel Apparatus Providers Big science has moved on to proteins. With the new brand of science termed proteomics--named by the Australians Marc Wilkins and Keith Williams to mean the "set of PROTEins encoded by the genOME"--the push is on around the globe to produce a complete description of a cell/tissue/organism in terms of the proteins produced. The challenge is all the greater because the expressed protein pattern changes with time and environment--responding to developmenta
Platelets Flag Bacteria in Mice
Tia Ghose | Oct 31, 2011 | 2 min read
Platelets play a role in capturing bacteria and initiating an immune response against them.
Sons of Next Gen
Tia Ghose | Jun 1, 2012 | 8 min read
New innovations could bring tailored, fast, and cheap sequencing to the masses.
The Heart of Europe's Biotech Sector
Martina Habeck | Aug 1, 2004 | 6 min read
More than 5,000 scientists with higher academic degrees work in public research in Europe's Upper Rhine valley, making this area one of the highest densities of life sciences-related research in the world. Now, the triangle region from Basel, Switzerland, in the south to Strasbourg, France, and Freiburg, Germany, in the north is striving to become the European heart of the biotechnology sector.The Dreiländereck or la Régio, as the region is called locally, has a lot going for it: excel

Run a Search

ADVERTISEMENT